Background: Cytogenetic abnormalities are the most important independent prognostic factors of acute leukemia and imply the potential molecular mechanism of the disease. Translocation (11;14)(p13;q11) has been predominantly found in T-cell acute lymphocytic leukemia (ALL) but is rare in B-cell ALL. Case Report: We present the case of a 30-year-old male patient, who presented with symptomatic anemia, thrombocytopenia and leukocytosis. Bone marrow aspirate smear showed hypercellularity with 90.4% of blast cells, which were negative for peroxidase reaction and partially positive for periodic acid-Schiff reaction. Immunophenotyping analysis was positive for CD34, HLA-DR, CD13, CD33, CD19, CD22, cCD79c, and negative for CD2, CD3, CD7, CD8, CD10, CD20, cCD3. Conventional cytogenetic study by R-banding showed complex chromosome aberrations involving t(11;14)(p13;q11) with the following karyotype: 46,XY,t (11;14)(p13;q11)[2]/46,idem,add2(q?)[2]/46,XY,add16(p?) [3]/46,XY[13]. Fluorescence in situ hybridization analysis indicated the translocation of chromosomes 11 and 14, and was negative for BCR/ABL fusion. The patient went into complete remission after the first induction chemotherapy (ALL-IC-BFM 2002 regimen), but he relapsed and died after 4 months. Conclusions: Translocation (11;14) (p13;q11) in B-cell ALL is rare, but it is worth exploring the molecular mechanisms and discovering the prognostic value in more B-cell ALL patients.

Keywords:
Acute lymphocytic leukemia, Chromosome, Fluorescence in situ hybridization
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.